Canadian Biopharma to Outlicense Pain Drug to South Korean Firm

Source: Streetwise Reports   09/12/2018 An Echelon Wealth Partners report discussed the deal terms. In a Sept. 5 research note, analyst Douglas Loe with Echelon Wealth Partners reported that Antibe Therapeutics Inc. (ATE:TSX.V; ATBPG:OTCQX) signed a [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.